Release Date: November 07, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you provide more color on the enrollment progress for the atopic dermatitis and alopecia areata studies? A: Mary Tagliaferri, Chief Medical Officer: We started the atopic dermatitis trial in October 2023 and expect top-line data in the first half of 2025. We will update the status on clinicaltrials.gov once enrollment is complete. The Phase 1 study was in biologic-naive patients, and we have continued this approach in the Phase 2b study. It's too early to predict efficacy in biologically experienced patients.
Q: When could damages be publicly specified in the ongoing litigation against Eli Lilly? A: Howard Robin, President and CEO: We can't comment on ongoing litigation specifics. We are in mediation and believe we have a strong case. However, I can't provide a timeline for when damages will be specified.
Q: Can you remind us of the protocol for topical steroid use in the Phase 2b atopic dermatitis trial? A: Mary Tagliaferri, Chief Medical Officer: This is not a combination trial. Patients must wash out of topical corticosteroids before enrolling and cannot use them during the study. Use of rescue medication after the first two weeks leads to discontinuation from the study.
Q: Can you provide some color on the patient baseline characteristics in the atopic dermatitis trial? A: Mary Tagliaferri, Chief Medical Officer: The study is fully blinded, and we are not reviewing aggregated data at this time. We will provide clear baseline characteristics and top-line data for the different doses compared to placebo once available.
Q: Regarding the alopecia areata study, why has the timing shifted to the second half of 2025? A: Mary Tagliaferri, Chief Medical Officer: The trial began about five months after the atopic dermatitis study. We are enrolling in the US, Canada, and Europe. The timing shift is due to the longer process of bringing European sites online, but we are on track to have data in the second half of 2025.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。